COMT and Parkinson disease: Current dopaminergic agents, anticholinergics, monoamine oxidase B (MAO-B) inhibitors, and catechol-O-methyltransferase (COMT) inhibitors relieve PD symptoms [19], but neither halt PD progression nor cross the blood–brain barrier (BBB) to deliver anti-inflammatory therapies.